Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.

An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.

The company scraps its lead project and clears out its C-suite, but there was already a precedent.

The company dribbles out more data on IMA203, and the numbers head in the right direction.

The sale of remaining rights to Allogene ends acrimony between the two companies.

ASCO is fast approaching, but in the meantime Olema will have an important readout.

Keyvibe-010 fails, but not for the reason you might have expected.

Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.